睾丸生殖细胞肿瘤的分子病理学:病理医师实践更新
本文综述睾丸生殖细胞肿瘤(TGCT)的分子分类:Ⅰ型(青春期前畸胎瘤/卵黄囊瘤)、Ⅱ型(GCNIS相关,含精原细胞瘤等)、Ⅲ型(精子细胞瘤)。常见分子改变包括Ⅱ型12p等臂染色体或12p获得,精原细胞瘤可见c-Kit或KRAS突变,TPS3突变/MDM2扩增与体细胞型恶变及顺铂耐药相关。血清标志物(AFP、hCGβ、microRNA)有助诊断与随访。
要点
- TGCT分三型:Ⅰ型青春期前型、Ⅱ型GCNIS相关、Ⅲ型精子细胞瘤。
- Ⅱ型常见12p等臂染色体或12p获得,精原细胞瘤可见c-Kit或KRAS突变。
- TP53突变或MDM2扩增与体细胞型恶变及顺铂耐药相关。
核心结论
- TGCT基于GCNIS相关性和分子改变分为三型,分子检测有助诊断但靶向治疗机会罕见。
研究设计与样本
- 综述,总结睾丸肿瘤当前分类、分子分类及诊断生物标志物。
主要发现
- Ⅰ型TGCT常见染色体异常,罕见Wnt信号通路改变。
- Ⅱ型TGCT常见12p等臂染色体或12p获得,精原细胞瘤可见c-Kit或KRAS突变。
- TP53突变或MDM2扩增及表观遗传改变与体细胞型恶变和顺铂耐药相关。
- Ⅲ型精子细胞瘤常见9号染色体(含DMRT1)扩增或Ras突变,部分可见12号染色体重叠改变。
关键数值与推荐
- Ⅱ型TGCT以12p等臂染色体或12p获得为常见分子改变。
- 精原细胞瘤可检测到c-Kit或KRAS突变。
- 晚期病例中KRAS G12C或BRAF V600E等靶点突变罕见,难以开展大样本研究。
临床怎么用
- 病理医师应结合形态学与分子改变(如12p、c-Kit、KRAS)辅助TGCT分型诊断。
- 血清AFP、hCGβ及microRNA可用于诊断和随访监测复发或进展。
- 病理报告需为泌尿外科和肿瘤内科提供分型、分子及预后相关信息。
局限性
- 靶向可操作改变罕见,难以开展大样本研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Testicular tumours are a diverse group of tumours, but most cases fall into the category of testicular germ cell tumours (TGCT). TGCTs are classified as either derived from a germ cell neoplasia in situ (GCNIS) or unrelated to GCNIS. Based on the development, molecular alterations and onset of development, TGCTs can further be divided into three groups. Type I TGCTs include prepubertal-type teratoma and yolk-sac tumour. Type II TGCTs are the only GCNIS-related tumours in this classification and include seminomas, embryonal carcinoma, choriocarcinoma, yolk-sac tumour and teratoma of postpubertal type. Type III TGCTs only include spermatocytic tumours. While genetic alterations are helpful in the diagnostic routine, they have not yet been useful in determining treatment options, as targetable alterations are very rare. Type I TGCTs most commonly exhibit chromosomal aberrations and rarely display alterations related to the Wnt signalling pathway. A common molecular alteration in type II TGCTs is the presence of an isochromosome 12p or gain of 12p material. It is thought that the isochromosome 12p develops during the progression of a GCNIS to an invasive TGCT. Seminomas can also exhibit c-Kit mutations or KRAS mutations. Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations. In advanced cases, some of these genes might be useful as targeted therapies (e.g. KRAS G12C or BRAF V600E), but as these mutations are rare, studies on larger groups of patients are not possible. Amplification of chromosome 9 including the DMRT1 gene, or Ras mutations is common in spermatocytic tumours. Overlapping molecular alterations, including those on chromosome 12, have recently been discovered in some type III TGCT. Tumour serum markers (e.g. alpha-fetoprotein, beta-subunit of human gonadotropin and microRNAs) are helpful in the diagnosis and for follow-up analysis to detect recurrent disease or disease progression. This review article provides an overview of the current classification of testicular tumours and their molecular classification. Furthermore, it provides information on biomarkers that are helpful in the diagnostic setting. Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists.
引用
- Fichtner A, Zschäbitz S, Nettersheim D, et al. Molecular pathology of testicular germ cell tumours: an update for practicing pathologists. Histopathology. 2026. PMID: 41384700. doi:10.1111/his.70040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。